All In Biotech

Drug Trial Radar · NCT00486785

SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study

Last checked: Nov 20, 2026Latest source record: Sep 30, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

431

Actual

Start

Apr 2006

Primary completion

Oct 2007

Study completion Mar 2008

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * To assess the sexual function improvement from baseline to the end of treatment (Week 24 or premature withdrawal (PW)) with XATRAL 10mg OD. Secondary Objective: * To evaluate the association between Lower Urinary Tract Symptoms (LUTS) severity and sexual disorders, * To compare the improvement in sexual function, urinary symptoms and Quality of Life among the different regions, * To correlate MSHQ (Male Sexual Health Questionnaire) and IIEF-5 (the 5-Item version of the International Index of Erectile Function), * To assess the onset of action of XATRAL 10mg OD, * To assess the peak flow rate improvement (Qmax), * To assess the safety and the tolerability of XATRAL 10mg OD.

Conditions

  • Prostatic Hyperplasia

Interventions

  • AlfuzosinDrug

    Alfuzosin 10mg Once Daily for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline to the end of treatment in the Male Sexual Health Questionnaire(MSHQ) for sexual function.Time frame: 24 weeks
  2. Evaluation of adverse events, vital signs (blood pressure and heart rate), PSA (Prostate-specific antigen; mandatory at baseline and optional at the end of treatment) and serum creatinine assessment (optional at baseline and at the end of treatment)Time frame: 24 weeks

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Bogotá, Colombia

  • Sanofi-Aventis

    Quito, Ecuador

  • Sanofi-Aventis

    Guatemala City, Guatemala

  • Sanofi-Aventis

    México, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.